Allergy Immunotherapy denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Allergy Immunotherapy as "Duplicate Therapy" — and Why You Can Appeal

A duplicate-therapy denial means Humana's system has identified another active claim for allergy treatment — typically another allergen immunotherapy series, sublingual drops, or an antihistamine or biologic also billed concurrently — and flagged the requested immunotherapy as redundant. This denial is often a billing or timing issue rather than a true clinical conflict, and it is frequently overturned when the prescriber documents that the two treatments are clinically distinct in mechanism, allergen target, or route.

## Federal Appeal Rights

• ACA Section 2719 external review is available for most individual and employer plans; you generally have approximately four months from the denial notice to file.
• ERISA Section 503 (employer-sponsored plans) entitles you to a written explanation of exactly which "duplicate" therapy was identified and the policy basis for the determination.
• If Humana cannot identify a specific overlapping claim, the denial must be overturned on internal appeal.
• Expedited review is available if delay causes clinical harm (e.g., immunotherapy maintenance interrupted mid-series).

## Concrete Appeal Steps and Timeline

1. Obtain the denial letter and EOB; request in writing that Humana identify the specific claim or service it considers duplicative. 2. Confirm with your allergist whether both treatments are actually active, or whether one was discontinued, completed, or billed in error. 3. File a Level 1 internal appeal with documentation that the two therapies are clinically distinct or that the alleged duplicate is no longer active. 4. If the duplicate was a billing error by the provider, obtain a corrected claim or a provider attestation and resubmit alongside the appeal. 5. If upheld internally, file for external review.

## Documentation to Gather

• Prescribing allergist's letter explaining the clinical rationale for the current immunotherapy course and how it differs from any other therapy flagged as duplicate
• Treatment records showing the start, duration, and current status of all allergy therapies in the relevant timeframe
• Documentation of any discontinued prior therapy (discharge summary, provider note, or end-of-series record)
• Applicable practice guidelines from the relevant allergy/immunology specialty organization (e.g., the American Academy of Allergy, Asthma & Immunology) confirming the therapeutic distinction

## Criteria-Mapping Structure

Locate Humana's allergy immunotherapy coverage policy in their online clinical policy library. For each duplicate-therapy criterion:

| Humana Criterion (from policy) | Supporting Documentation | |---|---| | Definition of "duplicate" (same mechanism / same allergen target) | Allergist letter distinguishing therapies | | Active concurrent therapy requirement | Treatment dates for each therapy | | Clinical necessity of concurrent or sequential treatment | Specialty society guideline reference |

Your appeal should state precisely which therapy Humana identified as the duplicate, demonstrate that the clinical distinction is documented in the chart, and request that Humana apply their published policy to the actual facts.